Peptide Industry News: May 2026 Market Report

The peptide therapeutics market is undergoing its most transformative period in history. Market projections now place the industry at $81.5 billion by 2034, driven by GLP-1 dominance, oral delivery breakthroughs, and over 150 peptides advancing through clinical trials. Eli Lilly and Novo Nordisk are battling for market share with competing oral obesity drugs, while major acquisitions—including Eli Lilly's $7.8 billion Centessa deal—signal pharmaceutical giants are consolidating peptide capabilities. This report covers the critical developments shaping the peptide landscape in May 2026.

What Are the Biggest Peptide Industry Developments in 2026?

The first half of 2026 has delivered seismic shifts across the peptide therapeutics sector. Three converging forces are reshaping the market: the GLP-1 oral revolution, unprecedented M&A activity, and regulatory recalibration.

Market Scale Reaches New Heights

The global peptide therapeutics market continues its aggressive expansion:

• $146.34 billion projected market size for 2026
• $334.95 billion forecasted by 2034 (10.91% CAGR)
• 61.99% market share held by North America
• 34 peptide drugs approved by the FDA in the last eight years alone

The explosive commercial success of GLP-1 receptor agonists has catalyzed unprecedented investment in peptide drug development, with the global pipeline expanding approximately 25% year-over-year since 2023.

Major Acquisitions Signal Industry Consolidation

Pharmaceutical giants are aggressively acquiring peptide capabilities:

These deals reflect a strategic bet on peptide platforms as the next wave of pharmaceutical innovation beyond GLP-1 weight loss drugs.

How Are Eli Lilly and Novo Nordisk Competing in 2026?

The duopoly dominating the GLP-1 market is experiencing its first major divergence. While both companies are racing to establish oral obesity treatments, their 2026 trajectories are heading in opposite directions.

Diverging Financial Outlooks

Eli Lilly has forecasted 2026 sales of $80-83 billion, representing approximately 25% growth and surpassing analyst expectations of $77.62 billion. The company has also overtaken Novo Nordisk in GLP-1 market share outside the United States.

Novo Nordisk, in contrast, has warned that sales and profits will decline 5-13% in 2026 due to U.S. pricing pressure and exclusivity expiring for blockbuster drugs in China, Brazil, and Canada.

The Oral Pill Race

2026 marks the definitive arrival of GLP-1 obesity pills:

Novo Nordisk's Wegovy Pill:

• First FDA-approved GLP-1 pill for obesity
• Tens of thousands of patients enrolled within four months of U.S. launch
• Requires taking with no more than 4 oz of water, then waiting 30 minutes before eating
• Self-pay pricing: approximately $349/month

Eli Lilly's Orforglipron (Foundayo):

• Approved April 2026
• Small-molecule drug absorbed more easily than peptide pills
• No dietary timing restrictions required
• Pricing: $299-449/month via LillyDirect

Orforglipron's small-molecule structure gives it an advantage: patients don't need to follow the restrictive dosing protocols required by Novo's peptide-based pill. However, Novo's head start has given Wegovy pills stronger early adoption numbers.

Pricing Reset Underway

Both companies have dramatically reduced self-pay pricing through direct-to-consumer channels, signaling acceptance that the days of $1,000+/month GLP-1 treatments are ending:

• Ozempic/Wegovy (Novo): ~$349/month via direct channels
• Zepbound (Lilly): $299-449/month via LillyDirect

This pricing pressure is a key driver behind Novo's projected revenue decline and represents a structural shift in how obesity medications reach patients.

What Is the FDA's Current Position on Peptides?

The regulatory landscape for peptides is undergoing its most significant recalibration in years, with major implications for both pharmaceutical companies and compounding pharmacies.

Category Reclassification in Motion

In February 2026, HHS Secretary Robert F. Kennedy Jr. announced that approximately 14 of 19 peptides previously placed on the FDA's Category 2 restricted list would be moved back to Category 1, potentially restoring compounding eligibility.

On April 15, 2026, the FDA removed 12 peptides from Category 2. The formal regulatory action took effect April 23, 2026.

Upcoming PCAC Meeting

The FDA has scheduled a critical Pharmacy Compounding Advisory Committee (PCAC) meeting for July 23-24, 2026 at the White Oak Campus in Silver Spring, Maryland. Seven peptides are under review for potential Category 1 placement:

1. BPC-157
2. TB-500 (Thymosin Beta-4)
3. AOD-9604
4. Thymosin Alpha-1
5. CJC-1295
6. Ipamorelin
7. Epithalon

This review does not constitute approval but represents a regulatory pathway that could restore compounding eligibility for these widely-used research peptides.

GLP-1 Compounding Crackdown Continues

While some peptides may gain expanded access, the FDA is tightening restrictions on compounded GLP-1 medications:

• February 21, 2025: FDA declared the semaglutide shortage resolved
• April 2026: FDA proposed permanently excluding semaglutide, tirzepatide, and liraglutide from the 503B bulks list
• June 29, 2026: Comment period deadline for the proposed rule
• 455+ adverse event reports linked to compounded semaglutide
• 320+ adverse event reports associated with compounded tirzepatide

If finalized, 503B outsourcing facilities would be permanently prohibited from compounding these GLP-1 agents from bulk substances.

What Peptides Are Currently in Clinical Trials?

The peptide clinical pipeline has never been more robust. As of early 2026, over 150 peptide-based drugs are in active clinical development, spanning metabolic diseases, oncology, infectious diseases, neurology, and regenerative medicine.

Most Watched Clinical Candidates

Retatrutide (Eli Lilly)

• Class: Triple GLP-1/GIP/glucagon receptor agonist
• Status: Phase 3 trials
• Significance: First triple agonist to reach Phase 3; early data suggests engaging all three receptors produces more robust metabolic effects than single or dual agonist approaches

Survodutide (Boehringer Ingelheim)

• Class: Dual GLP-1/glucagon agonist
• Status: Phase 3 trials
• Target: Obesity, MASH (metabolic dysfunction-associated steatohepatitis)

CagriSema (Novo Nordisk)

• Class: Semaglutide + cagrilintide combination
• Status: Phase 3 trials
• Target: Enhanced weight loss beyond semaglutide monotherapy

EB613 (Entera Bio)

• Class: Oral anabolic peptide
• Status: Phase 3 protocol submitted
• Target: Postmenopausal osteoporosis
• Significance: First oral anabolic peptide tablet for bone health

Oncology Pipeline Acceleration

Cancer research peptides are experiencing a breakthrough moment in 2026:

• Clinical trial registrations for peptide-based oncology compounds increased 34% year-over-year
• Three therapeutic classes leading development: checkpoint inhibitor peptides (PD-1/PD-L1 mimetics), antibody-drug conjugate linkers, and dual-action GLP-1/GIP agonists showing unexpected tumor suppression
• ADC linker peptides have achieved both stability and tumor-specific cleavage for the first time, using protease-cleavable linkers engineered around cathepsin B substrate sequences

AI Accelerating Discovery

Artificial intelligence is compressing peptide discovery timelines from years to months:

• 78% of peptide-drug conjugates entering clinical trials since 2022 utilized AI-optimized components (up from <15% before 2020)
• Tools like PepTune (2026 masked diffusion language model) can simultaneously optimize binding affinity, solubility, permeability, and hemolysis
• Machine learning models coupled with designed experiments now predict formulation performance before synthesis

How Is Manufacturing Capacity Expanding?

The surging demand for peptide therapeutics—particularly GLP-1 medications—has triggered massive investments in manufacturing infrastructure.

CDMO Capacity Surge

Contract development and manufacturing organizations (CDMOs) are racing to meet demand:

• CordenPharma: Committed €900 million to expand GLP-1 production capacity
• SK pharmteco (South Korea): Deploying $260 million for a new facility opening in 2026, focused on GLP-1 and oncology capacity
• Eli Lilly: Investing $6+ billion in a new active drug ingredient manufacturing facility in Huntsville, Alabama (construction begins 2026, completion targeted 2032; creating ~3,000 construction jobs and 450 permanent roles)

Regional Manufacturing Expansion

AstraZeneca announced a $2.5 billion investment in Beijing for a new R&D center, manufacturing facilities, and biotech collaborations—signaling that peptide manufacturing is becoming a global strategic priority.

What Oral Peptide Breakthroughs Are Emerging?

The oral delivery of peptides—long considered the "holy grail" of drug delivery—is finally reaching clinical reality.

The Bioavailability Challenge

With few exceptions, the bioavailability of most peptides following oral administration is less than 1%. The gastrointestinal tract presents multiple barriers: enzymatic degradation, poor membrane permeability, and large molecular size.

Current Solutions Reaching Market

Rybelsus (oral semaglutide): Despite only ~1% bioavailability, high potency allows clinical effectiveness. This proof-of-concept has opened the door for oral peptide development.

Orforglipron: Eli Lilly's small-molecule oral GLP-1 avoids the dietary restrictions required by peptide-based pills, representing a structural innovation rather than a delivery technology advance.

Next-Generation Delivery Technologies

Several breakthrough approaches are advancing through clinical development:

• Swallowable needle systems (LUMI, SOMA): Facilitate direct intestinal injection, bypassing absorption barriers
• Mesoporous carriers: Improve peptide stability and permeability
• Mucus-penetrating nanoparticles: Enhance retention and epithelial interaction
• Structural modifications: Lipidation, cyclization, and PEGylation improve membrane permeability

Novo Nordisk has announced multi-billion dollar investment into oral peptide platforms, with plans to develop oral versions of existing therapies and expand into cardiovascular disease, autoimmune disorders, and neurological conditions including Alzheimer's and Parkinson's.

Clinical Progress Beyond Weight Loss

Two oral peptide candidates are advancing in Phase 3 trials for non-metabolic indications:

• Enlicitide (MK-0616): Orally bioavailable PCSK9 inhibitor for adult hypercholesterolemia
• Icotrokinra (JNJ-2113): Oral peptide-based treatment for psoriasis

Key Takeaways

• The peptide therapeutics market is projected to reach $81.5 billion by 2034, with over 150 drugs currently in clinical development
• Eli Lilly and Novo Nordisk are diverging sharply—Lilly projects 25% growth while Novo braces for 5-13% decline due to pricing pressure
• Oral GLP-1 pills have arrived, with Novo's Wegovy pill gaining early adoption advantage despite Lilly's less restrictive dosing protocol
• Major acquisitions (Lilly/Centessa $7.8B, Novartis/Unnatural Products $1.7B) signal consolidation of peptide capabilities
• The FDA's July 2026 PCAC meeting will review BPC-157, TB-500, and five other peptides for potential Category 1 placement
• GLP-1 compounding faces permanent restrictions as the FDA proposes excluding semaglutide, tirzepatide, and liraglutide from the 503B bulks list
• AI is accelerating discovery, with 78% of recent peptide-drug conjugates utilizing AI-optimized components
• Manufacturing capacity is expanding rapidly, with billions invested in CDMO facilities globally

Frequently Asked Questions

How big is the peptide therapeutics market in 2026?

The global peptide therapeutics market is valued at approximately $146.34 billion in 2026 and is projected to reach $334.95 billion by 2034, representing a compound annual growth rate of 10.91%. North America holds the largest market share at 61.99%.

Which company is winning the GLP-1 market—Eli Lilly or Novo Nordisk?

As of May 2026, Eli Lilly has overtaken Novo Nordisk in GLP-1 market share outside the United States and projects 25% revenue growth. Novo Nordisk, facing pricing pressure and expiring exclusivity in key markets, forecasts a 5-13% decline in 2026 sales. However, Novo's oral Wegovy pill has gained stronger early patient adoption than Lilly's competing product.

What peptides are being reviewed by the FDA in July 2026?

The FDA's Pharmacy Compounding Advisory Committee is scheduled to review BPC-157, TB-500 (Thymosin Beta-4), AOD-9604, Thymosin Alpha-1, CJC-1295, Ipamorelin, and Epithalon at its July 23-24, 2026 meeting. These peptides are being considered for Category 1 placement, which could restore compounding eligibility.

Can pharmacies still compound semaglutide and tirzepatide?

The FDA is proposing to permanently prohibit 503B outsourcing facilities from compounding semaglutide, tirzepatide, and liraglutide from bulk substances. The semaglutide shortage was declared resolved in February 2025, and the FDA has received over 775 adverse event reports linked to compounded GLP-1 medications. A final rule is pending after the June 29, 2026 comment deadline.

What is retatrutide and why is it significant?

Retatrutide is Eli Lilly's triple receptor agonist that targets GLP-1, GIP, and glucagon receptors simultaneously. It is the first triple agonist to reach Phase 3 clinical development. Early data suggests that engaging all three receptors may produce more robust metabolic effects than single or dual agonist approaches currently on the market.

---

This content is for informational purposes only and is not medical advice. Consult a healthcare provider before using any peptides. Regulatory status and market conditions are subject to change.

Sources

• Peptide Therapeutics Market to Lead USD 81.5 Bn by 2034 - Towards Healthcare
• Eli Lilly's GLP-1 growth is only getting started as Novo Nordisk braces for a decline - CNBC
• Novo Nordisk's head start on GLP-1 pills - CNBC
• 2026 is the year of obesity pills from Novo Nordisk, Eli Lilly - CNBC
• Eli Lilly overtakes Novo Nordisk in GLP-1 market share outside US - GxP News
• FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List - FDA
• FDA's Pep(tide) Rally! What Compounders and Industry Need to Know - FDA Law Blog
• Peptides in Clinical Trials 2026: The Most Promising Pipeline - Peptide Protocol Wiki
• Clinical Trials for Peptide Drugs Are Surging - Peptide Wiki
• How Supply and Demand for Weight Loss Drugs is Playing Out in 2026 - J.P. Morgan
• Novo Nordisk Bets Big on Oral Peptide Therapies - Science Technology News
• From injections to pills: oral peptides set to transform drug development - Drug Target Review